Besides their cross-presenting ability, cDC1s also outstand at producing IL-12, CXCL9 and CXCL10 and at expressing costimulatory molecules, all of which contribute to effective T cell responses against cancer.1–3 10 Indeed, cDC1s mediate T cell priming and the generation of tissue-resident memory CD8+ T cells,11 a memory T cell subset that contributes to immunity against cancer.12 13 cDC1s also contribute to the reactivation of central memory CD8+ T cells in the context of tumors.12 Thus, it is not surprising that tumors select immune escape mechanisms to avoid cDC1 infiltration. The gene discussed is CXCL9; the disease is cancer.